DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for mucopolysaccharidosis type 3D — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMucopolysaccharidosis type 3D maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mucopolysaccharidosis type 3d is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The five abstracts provided do not concern mucopolysaccharidosis type 3D. They cover mucopolysaccharidosis type II (Hunter's syndrome), type I, and general mucopolysaccharidosis case reporting. No abstract mentions any drug, enzyme replacement therapy, or experimental treatment for MPS 3D. The 2015 case report on Hunter's syndrome notes a urinary glycosaminoglycan level of 69.6 mg/mmol against a normal range of 0.0–11.6 mg/mmol, and describes diagnostic barriers in a resource-limited country: late presentation, scarce and costly enzyme activity testing, and absent treatment infrastructure. The 2021 abstract on MPS I lists challenges including classification, neonatal screening, spinal and eye disease care, and allergic reactions to enzyme replacement therapy, but gives no efficacy data.
The 2014 case report describes radiological findings aiding diagnosis of MPS in a resource-poor setting, with no therapeutic content. The 2018 chapter on mucopolysaccharidoses and oligosaccharidoses is a general radiographic and clinical review, and the 2018 orthopaedic abstract reports on 20 MPS I patients, focusing on skeletal manifestations from early infancy, again without treatment outcomes. None of these sources provide survival statistics, response rates, or sample sizes relevant to MPS 3D, and none evaluate any candidate drug for that condition.
For a public drug-repurposing page on MPS 3D, this evidence base is unusable. The abstracts are off-target by disease subtype and contain no interventional data. What is missing is any clinical or preclinical study specifically enrolling MPS 3D patients, any pharmacokinetic or biomarker data for a repurposed compound in that population, and any trial design that stratifies by residual enzyme activity or genotype. Without those, no statement about efficacy, safety, or dosing can be made.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Ethiopian Journal of Health Sciences · 2015 · 5 citations · open access
Challenges in the Management of Mucopolysaccharidosis Type II (Hunter’s Syndrome) in a Developing Country: a Case Report
AbstractBACKGROUND: Mucopolysaccharidosis type II (Hunter's syndrome) is an X-linked chromosomal storage disorder due to deficiency of the lysosomal enzyme iduronate-2-sulfatase with patients rarely living till adulthood. Failure to identify patients early could contribute to an increased morbidity as identified in this case report. CASE DETAILS: An eight year old patient with Hunter's syndrome identified five years after disease onset with severe cardiovascular complications exemplifies the challenges faced in resource-limited countries towards making diagnosis and treatment of rare conditions. Elevated urinary glycosaminoglycans levels or a strong clinical suspicion of Hunter's syndrome, as identified in the index case, is a prerequisite for enzyme activity testing. Urinary mucopolysaccharide(MPS) level was 69.6 mg/mmol(normal range is 0.0 - 11.6 mg/mmol), and the confirming MPS electrophoresis analysis showed elevated heparan sulphate in the urine sample. Enzyme activity testing, with absent or very low iduronate-2-sulfatase activity, is diagnostic. However, the scarce availability and high cost of these tests is another constraint in making a diagnosis. CONCLUSION: Identification and management of mucopolysaccharidosis type II pose a problem in resource-constrained countries due to late presentation, lack of facility for diagnosis and treatment, cost and expertise required for the management.
Oxford University Press eBooks · 2018 · 1 citations
Mucopolysaccharidoses and Oligosaccharidoses
AbstractThis chapter discusses mucopolysaccharidoses and oligosaccharidoses and explores dysostosis multiplex, mucopolysaccharidosis IV, mucolipidosis II, and mucolipidosis III. Each discussion includes major radiographic features, major clinical findings, genetics, major differential diagnoses, and a bibliography.
Archivos Argentinos de Pediatria · 2021 · 0 citations · open access
A few challenges in mucopolysaccharidosis type I
AbstractHere we describe the current challenges of mucopolysaccharidosis type I: the need for an adequate classification, establishing its relationship to therapeutic indications; an early diagnosis, from neonatal screening, its advantages and barriers, to clinical suspicion of severe and attenuated forms; spinal and eye disease care, from diagnosis to follow-up and treatment; allergic reactions caused by enzyme replacement therapy, their diagnosis and treatment. And lastly, transition to adult care.
Journal of Chittagong Medical College Teachers Association · 2014 · 0 citations · open access
Mucopolysaccharidosis, A Rare Metabolic Disorder: A Case Report
AbstractMucopolysaccharidosis (MPS) is a type of storage disorders which can affect the skin, liver, spleen, eye, brain and bone. Some variant present in early infancy and others present in late childhood. Clinical, biochemical and radiological evaluations are needed for a conclusive diagnosis. We present a case of MPS with various radiological findings of spines and skull which helped in the diagnosis of the condition in a resource poor setting like that of us.
 JCMCTA 2013 ; 24 (2): 51-52
N N Priorov Journal of Traumatology and Orthopedics · 2018 · 0 citations · open access
Clinical manifestations of mucopolysaccharidosis type I (Orthopaedic aspects)
AbstractThe difficulties of differential diagnosis of mucopolysaccharidoses (MPS) type I are conditioned by low population rate of the pathology that results in untimely and inadequate treatment. Case reports for 20 patients with MPS I are presented. Special attention is paid to the orthopaedic manifestations of the pathology that can be determined since the first months of life.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
